Nkarta rises on FDA agreement for amended trial protocol [Seeking Alpha]
Nkarta, Inc. (NKTX)
Company Research
Source: Seeking Alpha
FDA to change the protocol of a clinical program that allows outpatient dosing of its lead asset, NKX019. The ongoing Ntrust-1 and Ntrust-2 clinical trials are designed to evaluate NKX019 in patients living with autoimmune diseases such as lupus nephritis and primary membranous nephropathy. As part of the amended trial protocol, a requirement for overnight stays will no longer be in force, the South San Francisco, California-based biotech said. It will also reduce the overall treatment burden on trial subjects, as community research centers and rheumatologists will be allowed to administer NKX019 in outpatient settings. “Reaching agreement with the FDA on outpatient dosing—reducing the need for patient monitoring from 24 hours to 2 hours—will reduce patient burden and expand access,” CEO Paul Hastings remarked. The company is on track to present initial data from Ntrust-1 and Ntrust-2 at a medical conference this year. Fresh Stock Ideas, Every Day More on Nkarta Seeking
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers [Yahoo! Finance]Yahoo! Finance
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersGlobeNewswire
- Nkarta to Participate in Needham Virtual Healthcare ConferenceGlobeNewswire
- Nkarta (NKTX) had its price target lowered by Mizuho from $14.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- Nkarta (NKTX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NKTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell"MarketBeat
NKTX
Earnings
- 3/25/26 - Miss
NKTX
Sec Filings
- 4/6/26 - Form EFFECT
- 4/3/26 - Form 424B5
- 3/26/26 - Form 8-K
- NKTX's page on the SEC website